Landing Point Financial Group’s Apellis Pharmaceuticals APLS Stock Holding History

Landing Point Financial Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,755	Closed	-$433K	–	101
2026 Q1	$433K	Buy	+10,755	New	+$232K	0.21%	57

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Landing Point Financial Group's APLS Position: Q2 2026 in Review

Landing Point Financial Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 10,755 shares — an estimated $433K sold.

Landing Point Financial Group first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $433K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Landing Point Financial Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Landing Point Financial Group sold 10,755 Apellis Pharmaceuticals shares in Q2 2026, an estimated $433K.
Landing Point Financial Group first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Landing Point Financial Group's Apellis Pharmaceuticals position peaked at $433K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Landing Point Financial Group's 13F filing for Q2 2026, filed 6 Aug 2026.